Erythropoietin (EPO) is the primary humoral regulator of erythropoiesis and no other factor has previously been reported to support proliferation and terminal maturation of erythroid cells from hemopoietic stem cells. Here we show that stimulation of glycoprotein (gp130) by a combination of recombinant human soluble interleukin 6 receptor (sIL-6R) and IL-6 but not sIL-6R or IL-6 alone can support proliferation, differentiation, and terminal maturation of erythroid cells in the absence of EPO from purified human CD34+ cells in suspension culture containing stem cell factor (SCF). A number of erythroid bursts and mixed erythroid colonies also developed in methylcellulose culture under the same combination. The addition of anti-gp130 monoclonal antibodies but not anti-EPO antibody to the same culture completely abrogated the generation of erythroid cells. These results clearly demonstrate that mature erythroid cells can be emerged from hemopoietic progenitors without EPO in vitro. Together with the previous reports that human sera contain detectable levels of sIL-6R, IL-6, and SCF, current data suggest that gp130 signaling in association with c-kit activation may play a role in human erythropoiesis in vivo.
Skip Nav Destination
Article navigation
1 March 1996
Article|
March 01 1996
Erythropoietin-independent erythrocyte production: signals through gp130 and c-kit dramatically promote erythropoiesis from human CD34+ cells.
X Sui,
X Sui
Department of Clinical Oncology, The Institute of Medical Science, The University of Tokyo, Japan.
Search for other works by this author on:
K Tsuji,
K Tsuji
Department of Clinical Oncology, The Institute of Medical Science, The University of Tokyo, Japan.
Search for other works by this author on:
S Tajima,
S Tajima
Department of Clinical Oncology, The Institute of Medical Science, The University of Tokyo, Japan.
Search for other works by this author on:
R Tanaka,
R Tanaka
Department of Clinical Oncology, The Institute of Medical Science, The University of Tokyo, Japan.
Search for other works by this author on:
K Muraoka,
K Muraoka
Department of Clinical Oncology, The Institute of Medical Science, The University of Tokyo, Japan.
Search for other works by this author on:
Y Ebihara,
Y Ebihara
Department of Clinical Oncology, The Institute of Medical Science, The University of Tokyo, Japan.
Search for other works by this author on:
K Ikebuchi,
K Ikebuchi
Department of Clinical Oncology, The Institute of Medical Science, The University of Tokyo, Japan.
Search for other works by this author on:
K Yasukawa,
K Yasukawa
Department of Clinical Oncology, The Institute of Medical Science, The University of Tokyo, Japan.
Search for other works by this author on:
T Taga,
T Taga
Department of Clinical Oncology, The Institute of Medical Science, The University of Tokyo, Japan.
Search for other works by this author on:
T Kishimoto,
T Kishimoto
Department of Clinical Oncology, The Institute of Medical Science, The University of Tokyo, Japan.
Search for other works by this author on:
T Nakahata
T Nakahata
Department of Clinical Oncology, The Institute of Medical Science, The University of Tokyo, Japan.
Search for other works by this author on:
X Sui
Department of Clinical Oncology, The Institute of Medical Science, The University of Tokyo, Japan.
K Tsuji
Department of Clinical Oncology, The Institute of Medical Science, The University of Tokyo, Japan.
S Tajima
Department of Clinical Oncology, The Institute of Medical Science, The University of Tokyo, Japan.
R Tanaka
Department of Clinical Oncology, The Institute of Medical Science, The University of Tokyo, Japan.
K Muraoka
Department of Clinical Oncology, The Institute of Medical Science, The University of Tokyo, Japan.
Y Ebihara
Department of Clinical Oncology, The Institute of Medical Science, The University of Tokyo, Japan.
K Ikebuchi
Department of Clinical Oncology, The Institute of Medical Science, The University of Tokyo, Japan.
K Yasukawa
Department of Clinical Oncology, The Institute of Medical Science, The University of Tokyo, Japan.
T Taga
Department of Clinical Oncology, The Institute of Medical Science, The University of Tokyo, Japan.
T Kishimoto
Department of Clinical Oncology, The Institute of Medical Science, The University of Tokyo, Japan.
T Nakahata
Department of Clinical Oncology, The Institute of Medical Science, The University of Tokyo, Japan.
Online ISSN: 1540-9538
Print ISSN: 0022-1007
J Exp Med (1996) 183 (3): 837–845.
Citation
X Sui, K Tsuji, S Tajima, R Tanaka, K Muraoka, Y Ebihara, K Ikebuchi, K Yasukawa, T Taga, T Kishimoto, T Nakahata; Erythropoietin-independent erythrocyte production: signals through gp130 and c-kit dramatically promote erythropoiesis from human CD34+ cells.. J Exp Med 1 March 1996; 183 (3): 837–845. doi: https://doi.org/10.1084/jem.183.3.837
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your Institution
Sign in via your InstitutionSuggested Content
Email alerts
Advertisement